Brazil's regulatory processes impair the growth of pharma industry

6 December 2013

The Brazilian pharmaceutical market is considered the second with the greatest growth potential in the world after China. However, a survey conducted by the Brazilian Center for International Relations (CEBRI) reconfirms that Brazil's current regulations still function as a growth barrier for the pharmaceutical industry, reports Juliane Carvalho on Brazil Pharma News.

A recent study published by the CEBRI was the theme of discussions around the so-called "Regulatory uniformity" of global supply chains and the development of the health industry in Brazil.

The study analyzed the current domestic market and offers suggestions for the creation of public policies promoting growth. The main purpose is to reduce the regulatory burden to facilitate exports and imports and, above all, the development of the pharmaceutical industry in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >